Global /United Kingdom /Industrials /Specialty Business Services /HVO
chevron_leftBack
hVIVO plc logo

hVIVO plc

HVO
LSE: HVO Delayed
8GBX 4.2%
0.1007 USD
As of 6 June 2026, hVIVO plc has a market cap of $66.41M USD, ranking #28492 globally and #652 in the United Kingdom. It ranks #6491 in the Industrials sector, and #752 in the Specialty Business Services industry.
Global Rank
28492
Country Rank
652
Sector Rank
6491
Industry Rank
752
Key Stats
Market Cap
$66.41MUSD
49.47M GBP
Enterprise Value
$67.06MUSD
49.96M GBP
Revenue (TTM)
$66.67MUSD
49.66M GBP
EBITDA (TTM)
-$847.12KUSD
-631.0K GBP
Net Income (TTM)
-$8.05MUSD
-5.99M GBP
EBITDA Margin
-1.3%
Profit Margin
-12%
PS Ratio
1.0
PB Ratio
1.3
EV/EBITDA
36.8
Company Profile
Country (HQ)
Sector
Industrials
Industry
Specialty Business Services
CEO
Yamin Khan open_in_new
Employees
376
Website
hvivo.com open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
4.2% -16% 18% 28% 17% -56%

News

Loading...

Markets

Exchange Ticker Price
London Stock Exchange
MIC: XLON
PRIMARY
HVO
hVIVO PLC
ISIN: GB00B9275X97
Shares Out.:
688.401M1 Shares Float: 676.808M2
TV:
SA:
YF:
GF:
BA:
HVO
MS:
8 GBX
Frankfurt Stock Exchange
MIC: XFRA
CRO
hVIVO PLC
ISIN: GB00B9275X97
Shares Out.:
687.014M1 Shares Float: 601.903M2
TV:
SA:
YF:
GF:
BA:
CRO
MS:
0.0750 EUR
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About hVIVO plc

hVIVO plc operates as a pharmaceutical service and contract research company in the United Kingdom, Europe, and North America. The company is involved in the testing of vaccines and antivirals using human challenge clinical trials; and provision of laboratory services, including assay development, cell based assays, molecular, immunology, virology, clinical field trail logistics, and biomarker analysis services. It has a portfolio of human challenge study models for conditions, such as RSV, influenza, COVID-19, hMPV, HRV, asthma, malaria, and COPD. In addition, the company offers specialized virology and immunology laboratory, which offers a suite of services to support pre-clinical and clinical respiratory drug; and vaccine discovery and development. Further, it provides pre­clinical and early clinical research services; sales and marketing services; data management; and statistics services, as well as drug development consultancy and services. The company offers services to big pharma and biotech organizations. The company was formerly known as Open Orphan Plc and changed its name to hVIVO plc in October 2022. hVIVO plc is headquartered in London, the United Kingdom.

Similar Companies

Industry: Specialty Business Services (United Kingdom)
Name
Market Cap diff.
PE
VSURE
$133.34B
114.8B EUR
201K%
-
REL
$63.91B
47.6B GBP
96K%
23.9
$16.54B
12.32B GBP
25K%
57.6
W
$13.48B
20K%
-
ITRK
$9.47B
7.05B GBP
14K%
21.3
KLAR
$5.08B
8K%
-
Industry: Specialty Business Services (Global)
Name
Market Cap diff.
PE
SHOP
$158.14B
238K%
129.8
CTAS
$69.6B
105K%
36.8
PYPL
$45.83B
69K%
9.4
$41.8B
56.91B CAD
63K%
-
XYZ
$41.37B
62K%
33.1
$41.33B
35.58B EUR
62K%
23.4
chevron_leftBack